NSE: CAMLINFINE | BSE: 532834

Expensive Rocket

Download real time

255.40 -13.40 (-4.99%)

173.45% Gain from 52W Low

326.1K NSE+BSE Volume

NSE 28 Jul, 2025 3:53 PM (IST)

4,799.5

Market Cap

Above industry Median

1.5

Beta 1Year

Very High Volatility

Camlin Fine Sciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CAMLINFINE, BSE:532834 Camlin Fine Sciences Ltd.

Camlin Fine Sciences Ltd.

19 Sep 2022

255.40

-4.99%

Pick of the Week:19 SEP 2022

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

We recommend a BUY rating on the stock with a near term TP of Rs 147, implying an upside of 14% from CMP.

Number of FII/FPI investors increased from 49 to 62 in Jun 2025 qtr.

Camlin Fine Sciences Ltd.

20 Sep 2021

255.40

-4.99%

Axis Annual Analysis:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Axis Direct

e maintain a BUY rating on the stock with an unchanged TP of Rs 215/share valuing the stock at 17x FY24E EPS.

Camlin Fine Sciences Ltd. is trading above its 200 day SMA of 171.8

Camlin Fine Sciences Ltd.

01 Jun 2021

255.40

-4.99%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

Owing to the strong growth guidance over FY21-23E our estimates undergo a revision leading to a revised TP to Rs. 215/share (Rs. 184/share earlier) and multiple of 18x on its FY23E EPS.

Camlin Fine Sciences Ltd. has lost -22.02% in the last 1 Month

Camlin Fine Sciences Ltd.

17 May 2021

255.40

-4.99%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

We maintain our BUY recommendation on CFS and value the stock at 16x FY23E EPS to arrive at a TP of Rs. 184/share, implying an upside of 12% from CMP.

Camlin Fine Sciences Ltd. has gained 53.37% in the last 3 Months

Camlin Fine Sciences Ltd.

19 Feb 2021

255.40

-4.99%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Axis Direct

We initiate coverage on Camlin Fine Sciences Ltd. (CFS) with a BUY recommendation and a Target Price of Rs. 155, which implies a 46% upside from current levels.

Camlin Fine Sciences Ltd. has gained 53.37% in the last 3 Months

Camlin Fine Sciences Ltd.

12 Feb 2019

255.40

-4.99%

Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on reven...

Buy: Camlin Fine Sciences Ltd.

Target

Emkay

Refer to important disclosures at the end of this report Going in right direction; maintain Buy Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on revenue and PAT front. Revenue up 17% yoy to Rs2.41bn (est. Rs2.29bn); EBITDA up 232% yoy to Rs154mn (est. Rs160mn); with net loss at Rs20mn (est. Rs36mn loss). CFIN's performance is headed in the right direction and well in line with our expectations. The key loss-making subsidiaries in Brazil and China are reaching a breakeven. Further,...

Camlin Fine Sciences Ltd.'s price crossed below 50Day SMA today

Camlin Fine Sciences Ltd.

17 Feb 2018

255.40

-4.99%

Camlin Fine Sciences' (CFIN) consolidated revenue grew by 54% yoy to Rs2.06bn (Emkay Est....

Buy: Camlin Fine Sciences Ltd.

Emkay

Camlin Fine Sciences' (CFIN) consolidated revenue grew by 54% yoy to Rs2.06bn (Emkay Est. Rs1.97bn) on the back of strong growth traction across key segments like Aroma (698% yoy), Blends (59% yoy), Performance (19% yoy) and Shelf-life (6% yoy). EBITDA stood at Rs46mn, up by 130% yoy but was lower than our estimate of Rs98mn on account of exceptional loss of Rs108mn (Loss: Forex -Rs57mn, China JV -Rs50mn)....

Camlin Fine Sciences Ltd.'s price crossed below 50Day SMA today

Camlin Fine Sciences Ltd.

06 Sep 2016

255.40

-4.99%

Picks of the week - Camlin Fine Sciences Ltd

Buy: Camlin Fine Sciences Ltd.

HDFC Securities

BUY Camlin Fine Sciences Ltd between Rs. 78- 70 for the target of Rs. 99, 117

Camlin Fine Sciences Ltd.'s price crossed below 50Day SMA today

Camlin Fine Sciences Ltd.

12 Aug 2016

255.40

-4.99%

Camlin Fine Q1FY17 Update 12Aug2016

Buy: Camlin Fine Sciences Ltd.

Phillip Capital

Key highlights: Consolidated sales (Rs 1.4bn, +14% yoy) were 4% above our estimates. EBITDA margin saw sharp correction to 11.2% (vs. estimated 21.2%) on account of – (1) production disruption in Italy subsidiary for a month period (for implementing efficient technology with target to conserve energy and reduce wastage) and initial marketing spend to launch antioxidant blends in USA. Thus, the EBITDA declined 45% yoy to Rs 157mn. The weak operating performance and higher taxes dragged PAT by 78% yoy to Rs 31mn (estimated Rs 116mn). The weak operating performance was primarily due to quarter specific execution issues at subsidiaries. The standalone financials reported 3% sales growth (to Rs 1.02bn) coupled with 160bps expansion in EBITDA margin (to 17.5%), resulting in 18% yoy growth in profits to Rs 65mn (despite higher tax incidence of 36%). Phillip Capital retain their Buy rating with an unchanged TP of Rs 135 (9x FY18 EV/EBITDA).

Camlin Fine Sciences Ltd. has gained 114.87% in the last 6 Months

Camlin Fine Sciences Ltd.

27 May 2016, 12:00AM

255.40

-4.99%

Camlin Fine Q4FY16 Update 27May2016

Buy: Camlin Fine Sciences Ltd.

Phillip Capital

9 Consolidated sales were lower than our estimates, but a smart >500bps surprise in marginsledto20%higherthanexpectedearnings. 9 FY16PATperformancewas10%aheadofourestimatesduetoa150bpspositivemargin...

Camlin Fine Sciences Ltd. is trading below its 30 day SMA of 301.0

Is Camlin Fine Sciences Ltd. worth buying?

240 Votes:

Buy 77.08%

Sell 14.17%

Hold 8.75%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf